Affibody is a Swedish biotechnology company that is revolutionizing the field of biologics through their unique proprietary technology platform. Their goal is to improve the lives of patients with serious diseases by developing next generation therapeutics. With a strong focus on autoimmune diseases and oncology, Affibody's pre-clinical and clinical development programs are making great strides in these areas.

In immunology, Affibody is conducting several clinical studies with their partner, exploring the potential of their drug candidates Izokibep and RLYB116 in IL-17 mediated diseases and complement mediated diseases, respectively. These studies have shown promising results, validating the potential of the platform to generate miniaturized multispecific protein drugs that address unmet medical needs. In the field of asthma, Affibody is developing a drug candidate that targets TSLP, a cytokine involved in inflammation processes.

This drug candidate has the potential to become a long-acting inhaled treatment with superior efficacy compared to other compounds. In oncology, Affibody has successfully demonstrated that their drug candidate effectively targets HER2-expressing tumors in patients with metastatic breast cancer. Supported by advanced imaging diagnostics, they are developing a radiation-based targeted precision drug for patients who no longer respond to conventional treatment.

Affibody's commitment lies in their focus on indications and target proteins where their technology platform gives them a competitive advantage and where there is a high unmet medical need. Through their innovative approach, they are redefining the possibilities in biotechnology